Holen Sie sich die Stockscreener-App
0.825
8.82%
-0.0798
Handel nachbörslich:
.77
-0.055
-6.67%
Atossa Therapeutics Inc Aktie (ATOS) Neueste Nachrichten
Atossa Therapeutics (ATOS) Stock: Soars 8% as FDA Grants Rare Pediatric Disease Designation for (Z)-Endoxifen (ATOS) - parameter.io
Why Are Shares Of Atossa Therapeutics Up Today? - Benzinga
Atossa Therapeutics Stock Jumps After FDA Grants Rare Pediatric Status To DMD Drug — Retail Bets On Phase 3 Fast-Track - Stocktwits
Atossa Therapeutics (ATOS) Surges on FDA Pediatric Designation - GuruFocus
Atossa gains on Rare Pediatric Disease status for Duchenne asset - Seeking Alpha
Atossa Therapeutics stock soars after FDA grants rare pediatric disease status By Investing.com - Investing.com Nigeria
Atossa Therapeutics stock soars after FDA grants rare pediatric disease status - Investing.com Nigeria
Atossa Therapeutics (ATOS) Gains FDA Recognition for Duchenne Mu - GuruFocus
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy - PR Newswire
Adversity is less terrifying than hope: Atossa Therapeutics Inc (ATOS) - setenews.com
Atossa Therapeutics Announces Issuance of U.S. Patent Covering E - GuruFocus
ATOS Receives New Patent for Endoxifen Formulations - GuruFocus
Atossa Therapeutics receives US patent for endoxifen formulations - Investing.com
Atossa Therapeutics (Nasdaq: ATOS) lands U.S. patent with 100 (Z)-endoxifen claims - Stock Titan
Ascendiant Capital Markets Forecasts Strong Price Appreciation for Atossa Genetics (NASDAQ:ATOS) Stock - MarketBeat
Ascendiant Capital Maintains Atossa Therapeutics (ATOS) Buy Recommendation - Nasdaq
Ascendiant Capital Raises Price Target for Atossa Therapeutics (ATOS) | ATOS Stock News - GuruFocus
Ascendiant Capital raises Atossa Genetics stock price target to $8 from $7.75 - Investing.com UK
CapEx per share of Atossa Therapeutics, Inc. – BER:YAG2 - TradingView
Analysts Set Atossa Genetics Inc. (NASDAQ:ATOS) Price Target at $6.25 - Defense World
Contrasting Vaso (OTCMKTS:VASO) and Atossa Genetics (NASDAQ:ATOS) - Defense World
Atossa Genetics stock holds Buy rating at H.C. Wainwright on FDA feedback By Investing.com - Investing.com South Africa
Atossa Genetics stock holds Buy rating at H.C. Wainwright on FDA feedback - Investing.com
Is Atossa Therapeutics Inc. stock undervalued vs historical averagesIPO Watch & Weekly Market Pulse Alerts - Newser
Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum - Finviz
Will Atossa Therapeutics Inc. stock outperform tech sector in 2025July 2025 Recap & Safe Capital Investment Plans - Newser
Is Atossa Therapeutics Inc. (YAG2) stock a buy before new product rolloutQuarterly Portfolio Report & Fast Momentum Entry Tips - Newser
Atossa completes FDA meeting on regulatory strategies - MSN
Atossa Completes FDA Meeting on Regulatory Strategies - TipRanks
Atossa Therapeutics Completes FDA Meeting on (Z)-Endoxifen Strategy - TradingView
Atossa Genetics Inc. (NASDAQ:ATOS) Given Average Rating of "Hold" by Analysts - MarketBeat
Is Atossa Therapeutics Inc. (YAG2) stock considered safe havenJuly 2025 Intraday Action & AI Driven Stock Movement Reports - Newser
Is Atossa Therapeutics Inc. (YAG2) stock good for long term investingWeekly Investment Summary & Low Risk Entry Point Guides - Newser
Will Atossa Therapeutics Inc. stock beat EPS estimates2025 Key Highlights & High Return Stock Watch Alerts - Newser
Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma - Lelezard
How Atossa Therapeutics Inc. (YAG2) stock performs in easing cyclesWeekly Trend Summary & Risk Controlled Stock Pick Alerts - Newser
Is Atossa Therapeutics (NASDAQ:ATOS) In A Good Position To Invest In Growth? - Sahm
Insilico Medicine and Atossa Therapeutics publish AI-driven study in Nature's Scientific Reports identifying (Z)-endoxifen as a potential therapeutic candidate for glioblastoma - EurekAlert!
S P Trends: How buybacks impact ARMOUR Residential REIT Inc stock valuePrice Action & Daily Profit Maximizing Trade Tips - BỘ NỘI VỤ
Atossa Therapeutics (ATOS) Advances Glioblastoma Research with A - GuruFocus
Can Atossa Therapeutics Inc. (YAG2) stock surprise with quarterly results2025 Momentum Check & Fast Gain Stock Tips - Newser
Published on: 2025-12-02 04:01:13 - Newser
Will Atossa Therapeutics Inc. (YAG2) stock hit Wall Street targetsOptions Play & Precise Trade Entry Recommendations - Newser
Atossa Therapeutics (ATOS) Stock Analysis Report | Financials & Insights - Benzinga
Will Atossa Therapeutics Inc. stock outperform international peersJuly 2025 Levels & Fast Moving Market Watchlists - BỘ NỘI VỤ
Is Atossa Therapeutics Inc (ATOS) positioned for future growth? - Setenews
Is Atossa Therapeutics Inc. stock a buy before product launches2025 Major Catalysts & Verified Momentum Watchlists - BỘ NỘI VỤ
Atossa Therapeutics Selects PSI as Contract Research Organization for Pivotal Dose-Ranging Study of (Z)-Endoxifen in Metastatic Breast Cancer (PR Newswire) - Aktiellt
Atossa Therapeutics, Inc. (ATOS) 5.16% in After-hours: What’s Driving the Move? - Stocks Telegraph
Atossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast Cancer (PR Newswire) - Aktiellt
Why Atossa Therapeutics Inc. (YAG2) stock is listed among top recommendationsRecession Risk & Verified High Yield Trade Plans - newser.com
Is Atossa Therapeutics Inc a good long term investmentTop Performing Stocks & Free Extraordinary Earning Power - earlytimes.in
How buybacks impact Atossa Therapeutics Inc. stock value2025 Momentum Check & Safe Investment Capital Preservation Plans - newser.com
Will Atossa Therapeutics Inc. (YAG2) stock profit from AI boomWeekly Profit Report & Fast Gaining Stock Reports - newser.com
Will Atossa Therapeutics Inc. (YAG2) stock remain on Wall Street radarWeekly Investment Report & Verified Short-Term Trading Plans - newser.com
1.08%
0.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):